Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Quidel Corporation expects highest quarterly revenue due to brisk sales of flu tests

Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid point-of-care diagnostic tests, announced today that it currently anticipates its highest quarterly revenue and operating income in its history, driven by global shipments of its QuickVue® Influenza A+B tests in the third quarter of 2009.

11 Sep 2009

Roche scientists use their xCELLigence System to analyze nutlin-induced apoptosis

The p53 tumor suppressor, a transcription factor that activates or inhibits hundreds of genes, either directly or indirectly, triggers a variety of cellular effects and plays a central role in the cellular defense against cancer. One of the main approaches for pharmacological intervention is to activate wild-type p53 in cancer cells by blocking MDM2 from binding to p53.

11 Sep 2009

Abstracts on Merck Serono oncology treatments to be presented at ECCO and ESMO

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, continues to drive the global effort to ensure patients receive personalized cancer therapies. A total of 17 abstracts concerning Merck Serono oncology treatments will be presented at the joint 15th Congress of the European Cancer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO), to be held in Berlin from 20-24 September 2009.

11 Sep 2009

Update on Prolindac clinical development plan provided by Access Pharmaceuticals

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), provided an update today on the Company's clinical development plan for ProLindac, a novel DACH platinum drug that has shown to be active in many solid tumor types in human clinical studies.

11 Sep 2009

Amylin and Biocon collaborate to develop a peptide therapeutic for treating diabetes

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Biocon, Limited (NSE: BIOCON) announced today that they have entered into an exclusive agreement to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin and Biocon will collaborate to develop the therapeutic potential of the compound and share development costs. Research will center on Amylin's "phybrid" technology.

11 Sep 2009

Phase 3 trial of ataluren commences

PTC Therapeutics, Inc. (PTC) today announced the initiation of a Phase 3 trial of ataluren (formerly PTC124(R)), an investigational protein restoration therapy in patients with nonsense mutation cystic fibrosis (nmCF).

11 Sep 2009

Phase II clinical trial of TAK-700 for treating advanced prostate cancer commences

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary Millennium: The Takeda Oncology Company today announced the initiation of the Phase II portion of a Phase I/II clinical trial of TAK-700 in patients with advanced prostate cancer.

11 Sep 2009

Medicare reimbursement cuts will affect cancer care system

The Community Oncology Alliance (COA), a national non-profit organization that represents oncologists and other cancer care providers, strongly opposes cuts in Medicare reimbursement for cancer care outlined by the Centers for Medicare & Medicaid Services (CMS).

11 Sep 2009

eChIP genetic technique developed to examine FA proteins with DNA crosslinks

While Fanconi anemia (FA) is a rare and dangerous disease, new laboratory research at The University of Texas M. D. Anderson Cancer Center shows it may lead researchers toward clues in more common diseases, including highly hereditary types of breast cancer.

11 Sep 2009

New Drug Application for trabectedin approved by the FDA

Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for trabectedin when administered in combination with DOXIL(R) (doxorubicin HCI liposome injection) for the treatment of women with relapsed ovarian cancer.

11 Sep 2009

FDA approves Supplemental New Drug Application for DOXIL

Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for DOXIL (doxorubicin HCI liposome injection) in combination with docetaxel for the treatment of women with locally advanced and metastatic breast cancer.

10 Sep 2009

Esperance Pharmaceuticals begins human clinical trials of its EP-100 cancer therapeutic candidate

Drug discovery and development company Esperance Pharmaceuticals today announced that it has begun enrollment and dosing of patients in a Phase 1 study of EP-100 in patients with advanced solid tumors. EP-100, the lead candidate from Esperance's Cationic Lytic Peptide (CLYP(TM)) platform technology, is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.

10 Sep 2009

GI Company's Phase II study demonstrates safety of rhITF oral spray formulation

Published today, as an original investigation, in the peer-reviewed Journal of Clinical Oncology, are statistically significant Phase II clinical results of The GI Company's lead clinical compound, rhITF (recombinant human Intestinal Trefoil Factor) oral spray. The article is titled, "A Phase II, Randomized, Double-blind, Placebo-Controlled Study of rhITF Oral Spray for Prevention of Oral Mucositis in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy."

10 Sep 2009

PinnacleCare and Champions Biotechnology collaborate to offer personalized oncology services worldwide

Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company whose personalized oncology services division assists physicians by providing personalized treatment options for their cancer patients, has entered into a collaboration agreement with PinnacleCare, the pioneer and the leading private health advisory company in the world.

10 Sep 2009

Roche conducts third Phase 1 clinical trial utilizing Halozyme’s Enhanze Technology

Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that the first patient was dosed in a Phase 1 pharmacokinetic clinical trial using Enhanze™ Technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation of a Roche biologic.

10 Sep 2009

Research on the impact of anti-smoking law in public places reveals that 5% of waiters have stopped smoking

Researchers from the Catalan Institute of Oncology have studied the impact of the law banning smoking in public places such as bars and restaurants on those working in these places. The results are positive - 5% of waiters have stopped smoking, and the number of cigarettes smoked by those who still smoke has fallen by almost 9%.

10 Sep 2009

EPO issues grant for a patent in Kreutzer-Limmer III patent series

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has issued a notification of intent to grant for a patent in the Kreutzer-Limmer III patent series (EP Application No 02702247.4). This patent series stems from the pioneering RNAi research performed by scientists at Ribopharma AG, which was acquired by Alnylam in 2003.

10 Sep 2009

New protocol to tackle postpartum depression

Up to 80 percent of women experience depressive symptoms postpartum, with one in eight reporting the emergence of major depression within weeks of delivery.

10 Sep 2009

Biovista's BVA-201 drug for MS shows positive results

Biovista Inc. today announced that BVA-201, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-201 is an existing drug that Biovista repositioned in MS and is aimed at neuroprotection. It was shown to have both efficacy in reducing symptoms and no toxic effects in this well established model of MS.

10 Sep 2009

Society of Interventional Radiology's resources emphasize on PAD

The Society of Interventional Radiology offers numerous resources just in time for September's national peripheral arterial disease (or PAD) awareness month. As recent medical studies continue to highlight the seriousness of PAD, these resources are welcome additions to libraries for interventional radiologists and primary care physicians who want to learn more about minimally invasive treatments for this disease that affects an estimated 10 million people in the United States.

10 Sep 2009

Oncology News and Research

Further Reading

Quidel Corporation expects highest quarterly revenue due to brisk sales of flu tests

Roche scientists use their xCELLigence System to analyze nutlin-induced apoptosis

Abstracts on Merck Serono oncology treatments to be presented at ECCO and ESMO

Update on Prolindac clinical development plan provided by Access Pharmaceuticals

Amylin and Biocon collaborate to develop a peptide therapeutic for treating diabetes

Phase 3 trial of ataluren commences

Phase II clinical trial of TAK-700 for treating advanced prostate cancer commences

Medicare reimbursement cuts will affect cancer care system

eChIP genetic technique developed to examine FA proteins with DNA crosslinks

New Drug Application for trabectedin approved by the FDA

FDA approves Supplemental New Drug Application for DOXIL

Esperance Pharmaceuticals begins human clinical trials of its EP-100 cancer therapeutic candidate

GI Company's Phase II study demonstrates safety of rhITF oral spray formulation

PinnacleCare and Champions Biotechnology collaborate to offer personalized oncology services worldwide

Roche conducts third Phase 1 clinical trial utilizing Halozyme’s Enhanze Technology

Research on the impact of anti-smoking law in public places reveals that 5% of waiters have stopped smoking

EPO issues grant for a patent in Kreutzer-Limmer III patent series

New protocol to tackle postpartum depression

Biovista's BVA-201 drug for MS shows positive results

Society of Interventional Radiology's resources emphasize on PAD

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News